




Please cite the Published Version

Tian, Zixing, Heald, Adrian H , Stedman, Mike, Fachim, Helene, Livingston, Mark , Gibson, Martin, Peng, Yonghong  and Ollier, William (2021) Age of people with type 2 diabetes and the risk of dying following SARS-CoV-2 infection. *International Journal of Clinical Practice*, 75 (8). e14053 ISSN 1368-5031

DOI: <https://doi.org/10.1111/ijcp.14053>

Publisher: Wiley

Version: Published Version

Downloaded from: <https://e-space.mmu.ac.uk/634939/>

Usage rights:  [Creative Commons: Attribution-Noncommercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/)

Additional Information: This is an open access letter published in *International Journal of Clinical Practice*

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

LETTER

METABOLISM & ENDOCRINOLOGY

Age of people with type 2 diabetes and the risk of dying following SARS-CoV-2 infection

Letter to the Editor

In 2020, the whole world has been challenged by the SARS-CoV-2 virus (Coronavirus-19).¹ Following coronavirus-19 infection people with diabetes are at higher risk than those who do not have diabetes, of becoming very unwell and in some cases dying.²⁻⁴ Notably, Barron et al⁴ reported an odds ratio (OR) of 2.03 (95% CI 1.97-2.09) for in-hospital coronavirus-19-related death in people with type 2 diabetes (T2DM). A body of work is emerging which is beginning to explain why people with diabetes are more likely to become seriously unwell following a coronavirus-19 infection. However, much of the detail remains to be determined.³

For people with diabetes, 2020 has been a very difficult year, with the awareness that their condition puts them at an increased risk of becoming very seriously unwell/dying following coronavirus-19 infection. It is, therefore, critical to determine all the factors that put any person with diabetes at an increased risk of a serious outcome after contracting a coronavirus-19 infection.

In one area of the United Kingdom (Salford) over the period of March-October 2020, we examined the potential risk factors relating to mortality in people with T2DM, who were confirmed as being coronavirus-19 positive. We examined health records for a representative sample of 308 T2DM people who were confirmed to be infected with coronavirus-19.

All data for this study were fully anonymised prior to analysis. The data were only released after the approval of the project by the Salford Integrated Record (SIR) Board.

Of these 56 people died, with the peak mortality rates seen in the months of April/May 2020. All patient data were fully anonymised prior to analysis.

Overall deaths for T2DM individuals living in Salford were 100% higher in March, 220% higher in April and 34% higher in May 2020 compared with the previous 5-year average monthly mortality rates for people with T2DM. Those who died following a confirmed coronavirus-19 infection were significantly older than those who survived (age \pm 95% confidence Interval (CI)) at 82.8 ± 10.3 vs 70.7 ± 14.8 years ($P < .001$). In multivariate logistic regression analysis, only age (Odds ratio (OR) (95% CI)) 1.07 (1.02-1.12) was the predictive of death following coronavirus-19 infection, independent of gender, glycosylated haemoglobin (HbA1c), diastolic blood pressure,

body mass index, serum creatinine, serum cholesterol, smoking status, and urine albumin/creatinine ratio. None of the other variables (than age) were statistically significant.

We were not able to include ethnicity in the analysis, as the sample included only a small number of people of non-Caucasian ethnic origin.

This analysis highlights the fact that age outweighs many other factors in people with T2DM in relation to mortality from the coronavirus-19 once infected, as previously proposed by McCullough et al⁵ in a paper advocating that age should be an important feature in risk stratification for early ambulatory treatment in the context of a Sars-Cov-2 (Covid-19) infection. The age factor should, therefore, be taken into account in relation to the vaccination programme against the coronavirus-19 in people with T2DM in the United Kingdom and elsewhere, while emphasising as always, support for concordance with lifestyle and pharmacological management in order to optimise the health of the individual.

ACKNOWLEDGEMENTS

None.

DISCLOSURE

None of the co-authors has any conflict of interest.

DATA SOURCES

The data used in the analyses presented were obtained with the permission of the Salford Integrated Record (SIR) board and were fully anonymised prior to being made available to the investigators.

Zixing Tian¹
Adrian H. Heald^{1,2} 
Mike Stedman³
Helene Fachim²
Mark Livingston^{4,5} 
Martin Gibson^{1,2}
Yonghong Peng⁶
William Ollier⁶

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *International Journal of Clinical Practice* published by John Wiley & Sons Ltd.

¹The School of Medicine and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK

²Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK

³Res Consortium, Andover, UK

⁴Black Country Pathology Services, Walsall Manor Hospital, Walsall, UK

⁵School of Medicine and Clinical Practice at the University of Wolverhampton, UK

⁶Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK

Correspondence

Adrian Heald, Department of Diabetes and Endocrinology,
Salford Royal NHS Foundation Trust, Salford, UK.
Email: adrian.heald@manchester.ac.uk

ORCID

Adrian H. Heald  <https://orcid.org/0000-0002-9537-4050>

Mark Livingston  <https://orcid.org/0000-0001-6878-0769>

REFERENCES

1. <https://www.who.int/health-topics/coronavirus>. Accessed December 24, 2020.
2. Tadic M, Cuspidi C, Sala C. COVID-19 and diabetes: is there enough evidence? *J Clin Hypertens (Greenwich)*. 2020;22:943-948.
3. Katulanda P, Dissanayake HA, Ranathunga I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. *Diabetologia*. 2020;63:1440-1452.
4. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol*. 2020;8:813-822.
5. McCullough P. Innovative early sequenced multidrug therapy for Sars-Cov-2 (Covid-19) infection to reduce hospitalization and death. *Int J Med Sci Clin Invent*. 2020;2020:5139-5150.